Cases & Deals

  • Home
  • Practices
  • Jemincare and RAPT collaborate to develop and commercialize JYB1904

Share

Jemincare and RAPT collaborate to develop and commercialize JYB1904

December 2024

Client(s) Shanghai Jemincare Pharmaceutical Co., Ltd.

Jones Day advised Shanghai Jemincare Pharmaceutical Co., LTD. (Jemincare), a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, on its exclusive license agreement with RAPT Therapeutics (Nasdaq: RAPT) for JYB1904, a clinical-stage, half-life extended anti-IgE monoclonal antibody. Under the terms of the license agreement, RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan to develop and commercialize RPT904. As consideration for the license, Jemincare is eligible to receive a $35 million upfront license fee, up to $672.5 million in additional payments upon the achievement of various regulatory and commercial milestones and royalties on future sales of RPT904 outside the Great China Area.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.